Previous 10 | Next 10 |
Eiger BioPharmaceuticals (NASDAQ: EIGR ) is up 3% premarket in reaction to U.S. Breakthrough Therapy designation for peginterferon lambda (Lambda) for the treatment of hepatitis delta virus (HDV) infection. More news on: Eiger BioPharmaceuticals, Inc., Healthca...
PALO ALTO, Calif. , Aug. 20, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that the Food and Drug Administration (FDA) has granted Breakthrough Th...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , iTunes...
Eiger BioPharmaceuticals (NASDAQ: EIGR ): Q2 GAAP EPS of -$0.75 beats by $0.01 . More news on: Eiger BioPharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
PALO ALTO, Calif. , Aug. 8, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today reported financial results for the three and six months ended June 30, 20...
PALO ALTO, Calif. , Aug. 5, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that management will participate in two upcoming investor...
In November last year when Eiger BioPharmaceuticals ( EIGR ) was trading near $9, The Total Pharma Tracker, run by Avisol Capital Partners, recommended a buy for the stock based on the following: this is a $184mn company with a year of cash runway, an NDA to be submitted in an indication ...
Baxter International (NYSE: BAX ) initiated with Sector Weight rating at KeyBanc. More news on: Baxter International Inc., Kadmon Holdings, Inc., Matinas BioPharma Holdings, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Gainers: MGI +117.9% . PHAS +14.0% . NSPR +7.4% . EIGR +4.9% . ARQL +2.7% . More news on: MoneyGram International, Inc., PhaseBio Pharmaceuticals, Inc., InspireMD, Inc., Stocks on the move, , News on ETFs Read more ...
News, Short Squeeze, Breakout and More Instantly...
Eiger BioPharmaceuticals Inc. Company Name:
EIGR Stock Symbol:
NASDAQ Market:
Eiger BioPharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Nikola Corporation (NKLA) rose 6.5% to $0.95 on volume of 182,734,103 shares WiSA Technologies Inc. (WISA) fell 3.3% to $0.0235 on volume of 160,634,740 shares PROSHARES TRUST (SQQQ) rose 4.7% to $11.12 on volume of 151,373,755 shares...
A look at the top 10 most actives in the United States Sunshine Biopharma Inc. (SBFM) rose 76.0% to $0.1065 on volume of 290,483,542 shares CXApp Inc. (CXAI) rose 151.0% to $6.15 on volume of 236,739,031 shares Nikola Corporation (NKLA) fell 1.0% to $1.03 on volume of 123,276,764 shares ...
Announces “Stalking Horse” Agreement for the Sale of Zokinvy ® (lonafarnib) Patient Access to Zokinvy ® to Continue Uninterrupted PALO ALTO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) today ...